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Nuclear inositides are involved in several processes, including DNA repair, transcrip-
tion regulation and RNA dynamics in normal and neoplastic conditions. Namely, nuclear 
phosphoinositide-phospholipase C (PI-PLC) beta1 plays an essential role in cell cycle 
regulation, mainly targeting cyclin D3. Moreover, PI-PLCbeta1 has been linked to the 
pathogenesis of myelodysplastic syndromes (MDS), i.e. clonal hematopoietic stem cell 
disorders characterized by ineffective hematopoiesis in one or more of the lineages of the 
bone marrow. Frequently, MDS result in a slow decrease in blood cell counts, but they 
may also show a worsening severe cytopenia or, in about 30% of all the cases, evolve into 
Acute Myeloid Leukemia (AML). Currently, azacitidine (AZA), a DNA methyltransferase 
inhibitor, is used to prolong survival and delay the MDS evolution into AML, alone or in 
combination with the histone deacetylase inhibitor valproic acid (VPA). 
In this study we analyzed the effect of AZA and VPA on inositide signaling pathways 
on high-risk MDS patients receiving AZA (75 mg/sqm/die SC for 7 days/28 days) and 
VPA (600-1.500 mg/die orally). We also studied the effect of AZA and VPA on HL60 cell 
line, which shows a hyper-methylation of PI-PLCbeta1 promoter and is affected by AZA 
treatment. Our results demonstrate that VPA enhances the effect of AZA on inositide sig-
naling pathways, increasing the demethylation effect induced by AZA on PI-PLCbeta1 
promoter and inducing gene and protein expression of other critical molecules. Taken 
together, our findings demonstrate for the first time that, at a molecular level, AZA and 
VPA can modulate key molecules of inositide signaling pathways, thus hinting at a role 
for these molecules as therapeutic targets for high-risk MDS. 
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